Back كوفيفاك Arabic CoviVac Catalan CoviVac (ruská vakcína) Czech CoviVac German CoviVac French CoviVac HE CoviVac ID CoviVac Italian CoviVac Japanese 코비박 코로나19 백신 (러시아) Korean
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Inactivated |
| Clinical data | |
| Routes of administration | Intramuscular |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
CoviVac (Russian: КовиВак) is an inactivated virus-based COVID-19 vaccine developed by the Chumakov Centre,[2] which is an institute of the Russian Academy of Sciences.[3] It was approved for use in Russia in February 2021, being the third COVID-19 vaccine to get approval in Russia.[2] It obtained a permission for phase III clinical trial on 2 June 2021.[4]
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ a b Ivanova P (20 February 2021). "Russia approves its third COVID-19 vaccine, CoviVac". Reuters. Retrieved 13 March 2021.
- ^ Abbany Z (9 March 2021). "Two more Russian vaccines: What we do and don't know". Deutsche Welle. Retrieved 13 March 2021.
- ^ Реестр разрешений на проведение клинических исследований лекарственных средств. (in Russian), Catalogue of permissions for conducting clinical trials of pharmaceuticals, 2 June 2021, Minzdrav